Research
Imperial College London & EMMAC Life Sciences

SHAPING THE FUTURE OF MEDICAL CANNABIS

EMMAC believes that the growth of the medical cannabis sector has to be underpinned by the most robust science. Our research partnership with Imperial College London involves the pre-clinical and clinical evaluation of cannabis-derived medicinal products including a feasibility randomised controlled trial for the treatment of perioperative pain, nausea and vomiting in major hepatopancreatobiliary surgery

The aims of the project are to:

  1. Investigate mechanisms of action of cannabis-based medicinal products related to several clinical applications including pain and cancer through in vitro and in vivo work
  2. Develop a clinical trial protocol for a feasibility randomised controlled trial and undertake necessary tasks related to regulatory pathways and subsequent practical elements of setting up and running such trial
  3. Characterise cannabis-based medicinal products in disease models with particular focus on chronic pain, spasticity and cancer

“We are delighted to partner with EMMAC Life Sciences and to collaborate on this exciting research programme. Translational research lies at the heart of our academic aims at Imperial College London and our first collaborative project illustrates the potential scope of cannabinoids to improve the quality of life and outcomes of patients undergoing surgery. As we gain a greater understanding of the therapeutic properties for a range of clinical conditions, this research will inform a portfolio of basic science work packages. This project is therefore the first step of a broad research programme aimed at shaping the global future of medicinal cannabinoid therapeutics.”

Professor Nagy Habib, Professor of Hepatobiliary Surgery at Imperial College London

“The strategic partnership with Imperial College puts EMMAC at the very forefront of research in the UK into the medical benefits of cannabis in relation to pain relief. As an industry, all participants must recognise that significant further research is needed to improve the understanding of the medical benefits of cannabis, with basic science and much greater clinical data under-pinning what we consider to be a huge potential market with enormous public health benefits (for patient and clinician).”

Antonio Costanzo, CEO of EMMAC

Speak to us